產(chǎn)品[
CRL-1631 Y3-Ag 1.2.3 大鼠骨髓瘤細(xì)胞
]資料
如果您對該產(chǎn)品感興趣的話,可以
產(chǎn)品名稱:
CRL-1631 Y3-Ag 1.2.3 大鼠骨髓瘤細(xì)胞
產(chǎn)品型號:
CRL-1631 Y3-Ag 1.2.3
產(chǎn)品廠商:
美國標(biāo)準(zhǔn)生物品收藏中心（ATCC）
產(chǎn)品文檔:
無相關(guān)文檔
簡單介紹
CRL-1631 Y3-Ag 1.2.3 大鼠骨髓瘤細(xì)胞，
ATCC 細(xì)胞|細(xì)胞系|細(xì)胞株|腫瘤細(xì)胞|細(xì)胞；細(xì)胞庫管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和培養(yǎng)條件！
CRL-1631 Y3-Ag 1.2.3 大鼠骨髓瘤細(xì)胞
的詳細(xì)介紹
CRL-1631 Y3-Ag 1.2.3 大鼠骨髓瘤細(xì)胞
|
Y3-Ag 1.2.3 |
|
K Yamada |
|
kappa light chain |
| Biosafety Level: |
1 |
|
frozen |
| Medium & Serum: |
See Propagation |
|
suspension |
|
Rattus norvegicus deposited as Rattus sp. |
|
lymphoblast
|
|
Disease: plasmacytoma; myeloma
Strain: Lou
Cell Type: B lymphoblast; |
|
immunoglobulin |
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. |
| |
|
the depositor has provided these cells for research purposes only and with the following restrictions: (1) no distribution should be made to third parties, (2) any proposed commercial use must be negotiated with the National Research Development Corporation, 101 Newington Causeway, London SE1 6BU, (3) all papers reporting any use of these or derived clones should make direct reference to the original publication (Nature 277:131-133, 1979) |
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C |
|
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml. |
|
culture medium 95%; DMSO, 5% |
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020 |
|
1090: Galfre G, et al. Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG. Nature 277: 131-133, 1979. PubMed: 310519
26115: Bazin H, et al. Transplantable immunoglobulin-secreting tumours in rats. I. General features of LOU-Ws1 strain rat immunocytomas and their monoclonal proteins. Int. J. Cancer 10: 568-580, 1972. PubMed: 4668496 |
